Phase 2 Sickle Cell Disease Trial, Recruiting (NCT06016634)

Phase 2 Sickle Cell Disease Trial, Recruiting NCT06016634 Sponsor: University of California, Davis Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06016634 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 80 years old and have been diagnosed with sickle cell disease (any type, confirmed by a blood test)
You are able to read and sign a consent form agreeing to take part in the study
You are able to lie still on a special bone density scanning machine (called a DXA scanner)
If you could potentially become pregnant, you must have a negative urine pregnancy test at the start of the study

Who may not be able to join:

You are currently pregnant
You are unable to give your own consent to take part in the study
You are under 18 years old (children, teenagers, or infants are not eligible)
You are currently in prison or a correctional facility
You have been admitted to a hospital for any reason within the 2 weeks before joining the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Oyebimpe O Adesina, MD, MS, UC Davis School of Medicine

Phone: (916) 460-2749

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06016634

Sponsor: University of California, Davis

Phase: Phase 2

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: (916) 460-2749

More information: https://clinicaltrials.gov/study/NCT06016634

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 80 years old and have been diagnosed with sickle cell disease (any type, confirmed by a blood test)
You are able to read and sign a consent form agreeing to take part in the study
You are able to lie still on a special bone density scanning machine (called a DXA scanner)
If you could potentially become pregnant, you must have a negative urine pregnancy test at the start of the study

Who may not be able to join:

You are currently pregnant
You are unable to give your own consent to take part in the study
You are under 18 years old (children, teenagers, or infants are not eligible)
You are currently in prison or a correctional facility
You have been admitted to a hospital for any reason within the 2 weeks before joining the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of California, Davis

Registry

ClinicalTrials.gov

Start date

9 March 2026

Est. completion

1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recruitment and retention rates; Incidence of Treatment-Emergent Adverse Events as assessed by participant report; Pain assessed by the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain Impact questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov